<DOC>
	<DOC>NCT01566526</DOC>
	<brief_summary>The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX速 in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX速 as part of the Belgium Medical Needs Program.</brief_summary>
	<brief_title>Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX速 Injections for Macular Oedema Secondary to Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) Received at least two OZURDEX速 injections in the study eye as part of the Belgium Medical Needs Program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>